Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
imidafenacin
- Development stage
- Phase 4
- Lead developer
- Kyorin Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Imidafenacin is a small molecule antimuscarinic (anticholinergic) agent used primarily for the treatment of overactive bladder (OAB), including symptoms such as urinary urgency, frequency, and urge incontinence. It acts by competitively antagonizing muscarinic acetylcholine receptors—mainly M3 and M1 subtypes—with high selectivity for bladder tissue over other organs. By blocking these receptors, imidafenacin reduces detrusor muscle contractions and inhibits acetylcholine release in the bladder, thereby decreasing urinary frequency and urgency. The drug was developed jointly by Kyorin Pharmaceutical and Ono Pharmaceutical and is marketed under the brand names Staybla (Ono) and Uritos (Kyorin), particularly in Japan[2][8][3][4].
- Brand names
- StayblaUritos
- Other names
- Imidafenacin [INN]ImidafenacinaImidafenacineimidafenacinum4-(2-Methyl-1H-imidazol-1-yl)-2,2-diphenylbutanamide
02
Targets
M1 (Muscarinic acetylcholine receptor M1)CHRM2 (M2)CHRM3 (M3)
Beyond the preview
Go deeper on imidafenacin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on imidafenacin.